Developing novel immunotherapies against medically-relevant targets utilizing Sorrento’s unique portfolio of proprietary OnTarget antibody technologies. Sorrento is an antibody-centric, clinical stage biopharmaceutical company focused on the discovery and development of safe and effective immunotherapies for oncology and autoimmune/inflammation diseases. Sorrento’s lead programs consist of four Phase III BioSimilar/BioBetter antibodies, and two Phase I CAR-T programs for treatment of solid tumors. Sorrento also is advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
COVID-19: Sorrento Therapeutics is collaborating with SmartPharm Therapeutics to develop a next-generation, gene-encoded antibody vaccine for COVID-19.
(07/2020) Picked up a saliva-based coronavirus test developed by fertility researchers at Columbia University (COVI-TRACE) that aims to provide an easy-to-read result in less than 30 minutes.